Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Carbiotix announces the launch of its second generation gut heath diagnostic platform

Carbiotix AB (publ) ("Carbiotix") announces today that the company will launch its second generation gut health diagnostics platform in Q1 of 2020. This platform will allow Carbiotix to attain a leading position in the diagnostics area by targeting a global market, which is estimated to be worth 800 million Euro for both consumer and clinical microbiome diagnostic services.Kristofer Cook, CEO for Carbiotix, comments “Carbiotix current diagnostic platform for gut health is based on a Fiber Loving Bacteria (FLB) Index, which is a simplified and cost-effective gut health test based on key

Clinical data for Episealer® to be presented at sports medicine congress in the United Kingdom

Episurf Medical (Nasdaq: EPIS B) today announces that its implant technology, and clinical results from the use of the Episealer® implant, will be presented at the sports medicine congress “Sports Knee 2019”. The congress will be arranged at St George’s Park Burton-on-Trent on November 25-26, 2019. The presentation will be held by Associate Professor Tim Spalding, University Hospitals Coventry and Warwickshire NHS Trust.  The clinical results come from a European multicenter study with 100 patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects

Promore Pharma AB (publ) Interim report January – September 2019

June – September · Net sales amounted to 1,3 (1,0) MSEK. · The operating loss for the period was 6,7 (-7,4)MSEK · Net loss was 6,7 (-7,6) MSEK corresponding to earnings per share of SEK -0,33 (-0,38) · Cash flow from operating activities amounted to -6,9 (-6,7) MSEK · Cash and cash equivalents amounted to 13,0 (39,5) MSEK January – September · Net sales amounted to 2,5 (1,1) MSEK · The operating loss for the period was 19,6(-26,1) MSEK · Net loss was 19,5 (-25,3) MSEK corresponding to earnings per share of SEK -0,96 (-1,25) · Cash flow from operating

Primary insider disclosure

Fornebu, 22 November 2019 The following primary insiders (or their related parties as described below) have, as part of the company’s incentive program, committed to acquire shares in Ocean Yield ASA (the "Company" or "Ocean Yield"): * Lars Solbakken, CEO, has through his wholly owned company Finmarine AS, committed to acquire 85,000 shares in Ocean Yield. Upon completion of such acquisition, Lars Solbakken will own 1,550,880 shares in the Company (all shares are owned indirectly through the wholly owned company Finmarine AS). * Andreas Røde, Head of Business Development & M&A.,

Akastor ASA: Øyvind Paaske appointed as CFO in Akastor

Øyvind Paaske has been appointed as Chief Financial Officer in Akastor ASA effective from 1 March 2020. He replaces Leif H. Borge who will remain in the position up to this date, after which he will assume a new position in a company outside the Aker group. Øyvind Paaske (35) joined the investment team in Akastor in 2014. Prior to this, he held the position as Investment Manager in Aker ASA. He holds an MSc in Financial Economics from the Norwegian School of Economics and Business Administration (NHH) and UNC Kenan-Flagler Business School. Akastor CEO Karl Erik Kjelstad says: “I am

2cureX publishes interim report for the third quarter of 2019

2cureX AB (“2cureX”) hereby publishes interim report for the third quarter of 2019. The interim report is available as an attached document as well as on the company’s website (www.2curex.com). Below follows a short summary of the report.CEO Ole Thastrup comments “We remain fully focused on the commercialization of IndiTreat with a planned launch of IndiTreat in 2020. Further, we push our multiple clinical studies to capitalize on a significantly increased interest for introducing 3D functional testing in cancer care. Pre-launch activities to support the market launch of IndiTreat® in

Enersize Oyj Interim Report for the third quarter of 2019

Enersize hereby presents the interim report for the period July - September 2019 and can show increasing turnover. Please note that this is not a financial report but primarily a summary of the most significant events during the past quarter. In information with the requirements of the Nasdaq Stockholm First North Growth Markets regulations, Enersize releases financial reports on a half- and full-year basis.The report (in Swedish) can be downloaded from Enersize's web page https://enersize.com/rapporter/.

Changes in Scandic’s organization to strengthen portfolio development

Scandic Hotels is making organizational changes to further strengthen its focus on developing the hotel portfolio. Svein Arild Steen-Mevold, who is currently Head of Scandic Hotels Norway, has been appointed as Chief Portfolio Officer with overall responsibility for Scandic’s portfolio management.Scandic’s hotel portfolio has grown rapidly in recent years and today, the Group is the clear leading hotel company in the Nordic countries. During the year, the company initiated a review of its portfolio in addition to working to make investment operations more effective and evaluating future

OrganoClick receives SEK 3.7 million in funding from strategic innovation program Bioinnovation for development of biobased binders for nonwoven

OrganoClick has been granted funding of SEK 3.7 million for development of its biobased binders for nonwoven used in hygiene and medical applications. The project will be executed in a Swedish-Finnish consortium including 3 players spanning the whole value chain from binder production (OrganoClick), a nonwoven producer and a product owner which manufactures hygiene and medical products for the healthcare sector. The project will be co-financed by the Swedish strategic innovation program BioInnovation – a joint program by Vinnova, Formas and the Swedish Energy Agency together with Business

SRV will implement a wellbeing centre in Kirkkonummi

SRV GROUP PLC     INVESTOR NEWS     22 NOVEMBER 2019      09:30 EET SRV will implement a wellbeing centre in Kirkkonummi SRV further bolsters its position as one of Finland’s largest builders of hospitals and healthcare buildings. The municipality of Kirkkonummi chose SRV to carry out the construction contract for the largest investment in its history, a new wellbeing centre. The investment is estimated to amount to a total of EUR 44.5 million, of which SRV’s share is about EUR 32 million. The project will be recognised in SRV’s order backlog in November. The Kirkkonummi wellbeing

INITIATOR PHARMA: Q3 2019 report

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016.  +--------------------------------------------+|Third Quarter (2019-07-01 – 2019-09-30) |+--------------------------------------------+| || · Net revenues were TDKK 0 (0) || · EBIT was TDKK -1,969 (-3,699) || · Earnings per share was DKK –0.08 (-0.21)|+--------------------------------------------+|

Interim Report January 1 – September 30, 2019

ChromoGenics acquires own sputtering capacity and strengthens the company’s strategy to have stable and quality-assured production of sputtered film for dynamic glassThird quarter of 2019 · Net sales for the period amounted to SEK 14.0 (0.0) million and earnings to SEK -20.0 (-12.5) million, which corresponds to earnings per share of SEK -0.07 (-0.30). Deliveries of backlogged customer orders for dynamic products were delayed during the quarter, which has meant that net sales have been postponed. · Gross profit amounted to SEK -4.9 million, which is a decrease of SEK -0.6 million

Redeye initiates coverage of Medicover

We initiate coverage on Medicover. Medicover has over twenty years of history of providing healthcare and diagnostic services to patients in Central and Eastern Europe (CEE) and has built a leading position in several of these fast-growing private healthcare markets. Despite a strong performance for the share in 2019, we believe the Medicover growth story still is underestimated by the market, and that the stock is currently trading at a discount to its peers. Read more and download the research update: http://bit.ly/339rBTV Start following companies at Redeye to receive the latest

AcadeMedia is awarded new contracts by the City of Stockholm

The City of Stockholm has announced its decision regarding the procurement for municipal adult education. The city distributes the responsibility for adult education to a limited number of providers, five of which are part of the AcadeMedia group – Movant, Eductus, Hermods, NTI-skolan and KompetensUtvecklingsInstitutet. The contracts were awarded based on criteria related to quality and fixed prices. The procurement decision includes eight contract areas and AcadeMedia has been awarded 13 new contracts in these areas. Among the contract areas included are Swedish for Immigrants, basic

Hexagon broadens its Smart Factory Solutions portfolio with the acquisition of Volume Graphics

Hexagon AB, a global leader in sensor, software and autonomous solutions, today announced the signing of an agreement to acquire Volume Graphics, a market leader in the industrial computed tomography (CT) software industry.Volume Graphics brings over 20 years of experience in non-destructive inspection and testing software development. The company’s high-end analysis and visualisation CT software enables manufacturers to produce three-dimensional external and internal representations of scanned objects. Using CT, they’re able to “see” inside the complicated structures of components,

Outcome of conversion of Swedish Stirling KV1

During the period from and including 1 October 2019 until and including 18 November 2019, holders of Swedish Stirling AB’s convertible bonds 2017/2019 (Nordic MTF: STRLNG KV1) (“KV1”) were entitled to convert their convertible bonds to shares in Swedish Stirling to a conversion rate of SEK 4.40 per share. Of the total outstanding loan amount of SEK 25,074,661 under KV1, an amount of SEK 24,575,623.60 has been requested for conversion, which corresponds to approximately 98 per cent.As a result of the conversion, Swedish Stirling’s share capital will increase with SEK 55,853.69 from SEK 795,

Skanska rebuilds school in Stockholm, Sweden, for about SEK 430 M

Skanska has signed a contract with Sisab Skolfastigheter i Stockholm AB regarding the redevelopment and expansion of Rödabergsskolan in Stockholm, Sweden. The contract is worth about SEK 430 million, of which about SEK 370 M will be included in the order bookings for Sweden for the fourth quarter 2019. The remaining part of the contract was booked in the previous quarter.The project includes the demolition of an existing school building, the construction of a new school building with a sports hall and also the reconstruction of the part of the school that is maintained. This is a total of

Moody’s downgrades Outokumpu’s corporate family rating and changes the outlook on ratings to stable

Outokumpu OyjPress releaseNovember 22, 2019 at 8.45 am EETMoody’s downgrades Outokumpu’s corporate family rating and changes the outlook on ratings to stable Moody’s Investors Service has decided to downgrade Outokumpu’s corporate family rating to B2 from B1 and the probability of default rating to B2-PD from B1-PD. Concurrently Moody’s downgraded the instrument rating of the Group’s senior secured notes due in 2024 to B1 from Ba3. The outlook of all ratings has been changed to stable from negative. For more information: Investors: Aki Vesikallio, Manager, Investor Relations,

Ferronordic AB (publ) Interim Report January - September 2019

Record strong third quarterTHIRD QUARTER 2019 · Revenue increased 22% (12% increase in local currency) to SEK 964m (SEK 791m) · Operating profit increased 36% to SEK 109m (SEK 80m) · Operating margin was 11.3% (10.1%) · The result for the period increased 22% to SEK 74m (SEK 61m) · Earnings per ordinary share amounted to SEK 5.09 (SEK 4.17) · Cash flows from operating activities amounted to SEK 95m (SEK 104m)  FIRST NINE MONTHS 2019 · Revenue increased 25% (21% increase in local currency) to SEK 2,787m (SEK 2,222m) · Operating profit increased 39% to SEK 262m (

Pandox acquires seven hotel properties in Germany for MEUR 290

Pandox AB (publ) has entered into an agreement to acquire seven hotel properties with a total of 1,532 rooms in Germany from HR Group. The total transaction value amounts to approximately MEUR 290, excluding minority. The acquisition is expected to be financed by liquid funds and new bank loans. The hotels will continue to be managed by HR Group under fixed leases with indexation, which will be converted into revenue-based leases by 2024 at the latest. The hotels are expected to contribute approximately MEUR 16.5 in rental income and MEUR 16.4 in net operating income, on an annualised basis.

Primary insider disclosure

Reference is made to the stock exchange release published by Ocean Yield ASA (“Ocean Yield”, “the Company”) on 21 November 2019 regarding a private placement of up to 15,935,143 new shares in the Company (“the Private Placement”).   Erøy AS, a company controlled by Øyvind Eriksen, President and CEO of Aker ASA, the majority shareholder of Ocean Yield, was allocated 75,000 shares in the Private Placement, at a purchase price of NOK 45. Following completion of the Private Placement, Erøy AS holds 325,000 shares in the Company, constituting 0.19 per cent of the Company’s shares and votes.

OCEAN YIELD: PRIVATE PLACEMENT SUCCESSFULLY COMPLETED

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange release by Ocean Yield ASA (“Ocean Yield” or the “Company”) on 21 November 2019 regarding a contemplated fully underwritten private placement (the “Private Placement”) of 15,935,143 new ordinary shares in the Company.

IRRAS Announces FDA Clearance of New 510(K) Filing to Expand the Time of Use of IRRAflow®

Stockholm, November 21, 2019 – IRRAS, a global healthcare company with a comprehensive portfolio of innovative products for neurocritical care, announced today that the US FDA has cleared a new 510(K) for IRRAflow. The application provided the FDA with supporting data demonstrating that extending the time of use of the product is safe and has the potential to be beneficial for patients. IRRAflow is the world’s first irrigating ventricular drain. Its unique mechanism of action addresses the complications associated with the current methods of managing intracranial fluid by using a dual

There are no items matching the current filter
There are no more items matching the current filter
Back to top